{
  "pmcid": "9090984",
  "sha256": "4c828b5826db90cab02637cda009e3dc6d7172a896f7df21fa452b2748f1fde6",
  "timestamp_utc": "2025-11-09T23:00:12.392767+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.594846938775511,
    "reading_ease": 26.582474489795942,
    "word_count": 245
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of N-acetylcysteine Plus Amiodarone for Prevention of Postoperative Atrial Fibrillation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "154 patients at high risk of postoperative AF undergoing major thoracic surgery were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "154 patients at high risk of postoperative AF undergoing major thoracic surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive N-acetylcysteine plus amiodarone or placebo plus amiodarone"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated whether N-acetylcysteine reduces postoperative AF incidence by mitigating inflammation and oxidative stress."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was sustained AF >30 s by telemetry or symptoms requiring intervention confirmed by ECG within 7 days post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "154 patients at high risk of postoperative AF undergoing major thoracic surgery were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Postoperative AF occurred in 15 of 78 patients (19%) receiving N-acetylcysteine and 13 of 76 (17%) receiving placebo"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "odds ratio, 1.24; 95.1% CI, 0.53â€“2.88; p = 0.615"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}